Stock Report

Download full stock data and analysis for free Last Updated: 03-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Exelixis (EXEL) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$58.26

up-down-arrow $0.32 (0.54%)

As on 02-Oct-2026 13:37EDT

Market cap

info icon

$14,411 Mln

Revenue (TTM)

info icon

$2,436 Mln

P/E Ratio

info icon

18.3

P/B Ratio

info icon

7.8

Div. Yield

info icon

0 %

Edit peer-selector-edit
Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)
 14,411 17,274 14,841 12,927 11,935
Revenue ($ Mln)
 2,436 2,782 1,054 1,664 1,284
Net Profit ($ Mln)
 860.62 491.50 755.85 413.60 -325.10
Net Margin (%)
 35.33 17.67 71.69 24.86 -25.32
RoE (%)
 42.98 110.09 -- 430.03 -57.72
Price to Earnings
 18.29 36.40 17.63 33.40 --
Price-To-Book
 7.82 39.70 8.91 88.91 22.63

Income Statement ($ Mln)

Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Operating Revenue arrow
2,435.92 2,782.29 1,054.37 1,663.74 1,283.94
Cost of Revenue arrow
85.67 1,982.07 103.47 363.07 109.42
Gross Profit arrow
2,236.43 760.62 588.53 1,091.18 902.26
Operating Expenses arrow
1,378.74 216.81 841.45 356.18 1,497.13
Operating Profit (EBIT) arrow
971.51 583.40 109.45 944.49 -322.62
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
1,035.47 598.92 101.11 583.34 -325.10
Provision for Tax arrow
174.84 107.42 -654.74 169.74 0.00
Profit after Tax (Net Income) arrow
860.62 491.50 755.85 413.60 -325.10
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds arrow
1,843.76 433.86 1,435.90 143.54 523.72
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
288.55 187.89 384.48 2,089.43 346.72
Current Liabilities arrow
361.93 1,435.43 464.70 344.44 374.20
Total Liabilities arrow
2,844.42 1,975.47 1,302.02 2,525.32 1,259.59

Assets ($ Mln)

Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Non-Current Assets arrow
1,243.41 1,006.90 895.24 1,644.38 45.47
Current Assets arrow
1,250.82 1,050.29 1,389.84 933.02 1,199.18
Total Assets arrow
2,844.42 1,975.47 1,302.02 2,525.32 1,259.59
Total Debt* arrow
165.93 120.10 449.89 2,146.65 347.75
Net Current Assets arrow
888.90 -385.14 925.52 588.59 824.98

Cashflow ($ Mln)

Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities arrow
884.27 713.22 51.77 651.56 -189.55
Cash Flow from Investing Activities arrow
350.44 -31.14 -8.15 -545.81 32.32
Cash from Financing Activities arrow
-969.59 -860.39 34.89 -85.17 255.98
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
ROCE (%) arrow
32.82 53.56 -30.01 15.61 -31.49
ROE (%) arrow
42.98 110.09 163.18 430.03 -57.72
ROA (%) arrow
29.32 15.64 31.68 16.19 -22.97
EBIT Margin (%) arrow
31.04 21.13 5.73 36.28 -18.97
Net Margin (%) arrow
35.33 17.67 71.69 24.86 -25.32
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%) arrow
9.23 24.67 114.85 41.15 149.04
EBIT Growth (%) arrow
-3.99 18.70 136.39 -14.99 9.16
Net Profit Growth (%) arrow
42.89 17.50 378.76 -25.78 -15.32
EPS Growth (%) arrow
50.42 26.84 353.27 -23.48 -0.64
Book Value Growth (%) arrow
-0.70 164.02 816.12 -55.81 -42.66

Valuation Ratios

 Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Price / Earnings arrow
15.79 36.06 -59.76 24.99 -45.32
Price / Book Value arrow
5.72 35.44 -80.42 162.23 21.68
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
12.44 28.08 -121.54 17.31 -47.02
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Debt to Equity arrow
0.00 0.00 0.27 13.50 0.65
Short term debt to equity ratio arrow
0.00 0.00 0.05 1.46 0.00
Current Ratio arrow
3.46 0.73 2.99 2.71 3.20
Quick Ratio arrow
3.38 0.73 2.32 2.31 2.94
Interest Coverage arrow
-- -- 1.62 29.73 -9.32

Operating Efficiency Ratios

 Exelixis (EXEL) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%) arrow
13.74 15.88 21.25 27.40 14.98
Asset Turnover arrow
0.83 0.89 0.44 0.65 0.91
Receivable days arrow
43.48 50.42 85.52 98.04 35.88
Inventory Days arrow
96.17 -- 1,056.70 190.34 354.23
Payable days arrow
147.97 6.26 331.01 18.62 300.79
Cash Conversion Cycle arrow
-8.32 -- 811.21 269.75 89.33
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...